

March 7, 2007

Recent Study Shows Significant Improvement in Knee Function and Joint Mobility Following Use of InflammAway™-Celadrin®

- Study awarded first place in 'Original Clinical Research Category' at Scripps
- Fourth clinical study on efficacy of Celadrin in past six years
- Validates superiority compared to competitors in market which exceeds \$2 billion

SAN DIEGO, March 7 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: [IAGX - News](#)), announced today that a new clinical study was presented at the 4th annual "Natural Supplements: An Evidence-Based Update" medical conference, hosted by Scripps Center for Integrative Medicine, has demonstrated that Celadrin® can significantly improve knee function and help relieve the painful symptoms of osteoarthritis. Findings were released by Imagenetix (www.imagenetix.net), an innovator in scientifically tested, natural-based bioceutical products and maker of InflammAway(TM)-Celadrin.

The new study -- the fourth clinical study performed on the efficacy of Celadrin during the past six years -- was conducted and presented by Jay Udani, M.D., at the Scripps Center for Integrative Medicine conference. Dr. Udani is a Medical Director of Medicus Research, Medical Director of the Integrative Medicine Program at Northridge Hospital and Assistant Clinical Professor at the UCLA/Geffen School of Medicine. The study was awarded first place in the "Original Clinical Research Category" competition.

The study reported that after eight weeks of taking Inflamm Away-Celadrin capsules, average walking ability increased 45 percent, and participants claimed a 35 percent decrease in knee discomfort. These improvements were statistically significantly better than the results seen in the placebo group, and no negative side effects were found throughout the entire study.

"This study demonstrates that after two weeks of taking Celadrin orally, subjects showed significant enhancement of their functional ability with progressive improvement continuing through the end of the 8 week study," said Dr. Udani.

The randomized, double-blind, placebo-controlled study, titled "Oral Cetylated Fatty Acids (Celadrin) for the Improvement of Functional Ability and Pain in Patients with Moderate Knee Osteoarthritis," evaluated 93 participants over a period of 60 days. Subjects, ranging from 40 to 86 years of age, were evaluated before Celadrin was administered and again after two, four and eight weeks. During each evaluation, participants were asked to walk for six minutes to measure how far they could travel with their knee discomfort.

The participants who consumed Celadrin were able to walk an average distance of 1183 feet when they started the study. After only two weeks of taking Celadrin capsules, the average walking distance increased significantly by about 19 percent, or approximately

232 feet. The participants continued to improve throughout the study period and after eight weeks of taking Celadrin capsules; the participants walked an average distance of 1720 feet -- 45 percent more than when they had started only two months before.

Non-prescription Inflamm-Away-Celadrin is available in two forms: a softgel and a topical cream application.

"Dr. Udani's study further supports the efficacy of Celadrin," said Robert Hesslink Jr., Sc.D., Director of Research and Development at Imagenetix. "Our studies conducted in the past have shown that Celadrin can be used to not only aid in osteoarthritis pain for aging individuals, but also to alleviate everyday joint discomfort for anyone who is physically active."

A study on the efficacy of Celadrin-based cream on patients with osteoarthritis, published in the Journal of Rheumatology in 2004, states that patients reported a significant relief in joint pain after only 30 minutes of application of the Inflamm-Away cream formula -- benefits which continued to improve over time with daily use of the product.

Inflamm-Away-Celadrin softgels and pain relieving cream are commercially available online through Costco Wholesale at www.costco.com and at Walgreens retail pharmacy locations nationwide. Inflamm-Away-Celadrin is the first product offered by Imagenetix under its own brand name.

"We are pleased with the results of this award winning study," said William Spencer, CEO of Imagenetix. "It validates Celadrin's significantly superior and proven joint health benefits compared to our competitors' glucosamine, chondroitin, MSM, SAME, and other natural based joint health products. Collectively these products represent a market that exceeds \$2 billion. Celadrin has once again clinically demonstrated that it works many times faster and is significantly more effective than glucosamine/chondroitin combined or any other natural joint health products on the market today."